Pulmonary vascular resistance predicts the mortality in patients with bronchiectasis-associated pulmonary hypertension.
| Autor: | Xu J; Department of Cardio-Pulmonary Circulation., Wang JJ; Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China., Zhao QH; Department of Cardio-Pulmonary Circulation., Gong SG; Department of Cardio-Pulmonary Circulation., Wu WH; Department of Cardio-Pulmonary Circulation., Jiang R; Department of Cardio-Pulmonary Circulation., Luo CJ; Department of Cardio-Pulmonary Circulation., Qiu HL; Department of Cardio-Pulmonary Circulation., Li HT; Department of Cardio-Pulmonary Circulation., Wang L; Department of Cardio-Pulmonary Circulation., Liu JM; Department of Cardio-Pulmonary Circulation. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of hypertension [J Hypertens] 2024 Oct 01; Vol. 42 (10), pp. 1703-1710. Date of Electronic Publication: 2024 Jun 10. |
| DOI: | 10.1097/HJH.0000000000003782 |
| Abstrakt: | Objective: Pulmonary hypertension is a severe complication of bronchiectasis, characterized by elevated pulmonary vascular resistance (PVR) and subsequent right heart failure. The association between PVR and mortality in bronchiectasis-associated pulmonary hypertension has not been investigated previously. Methods: In the present study, a retrospective analysis was conducted on 139 consecutive patients diagnosed with bronchiectasis-associated pulmonary hypertension based on right heart catheterization, enrolled between January 2010 and June 2023. Baseline clinical characteristics and hemodynamic assessment were analyzed. The survival time for each patient was calculated in months from the date of diagnosis until the date of death or, if the patient was still alive, until their last visit. Results: Patients with bronchiectasis-associated pulmonary hypertension exhibited estimated survival rates of 89.5, 70, and 52.9 at 1-year, 3-year, and 5-year intervals respectively, with a median survival time of 67 months. Multivariable Cox regression analysis revealed that increased age [(adjusted hazard ratio per year 1.042, 95% confidence interval (CI) 1.008-1.076, P = 0.015] and elevated PVR (adjusted HR per 1 Wood Units 1.115, 95% CI 1.015-1.224, P = 0.023) were associated with an increased risk of all-cause mortality. In contrast, higher BMI was associated with a decreased risk of all-cause death (adjusted hazard ratio per 1 kg/m 2 0.915, 95% CI 0.856-0.979, P = 0.009). Receiver-operating characteristic analyses identified a cutoff value for PVR at 4 Wood Units as predictive for all-cause death within 3 years [area under the curve (AUC) = 0.624; specificity= 87.5%; sensitivity= 35.8%; P < 0.05]. Patients with a PVR greater than 4 Wood Units had a significantly higher risk of all-cause death compared with those with 4 Wood Units or less (adjusted hazard ratio 2.392; 95% CI 1.316-4.349; P = 0.019). Notably, there were no significant differences in age, sex, BMI, WHO functional class, 6-min walk distance, and NT-proBNP levels at baseline between patients categorized as having 4 Wood Units or less or greater than 4 Wood Units for PVR. Conclusion: Based on these data, PVR could serve as a discriminative marker for distinguishing between nonsevere pulmonary hypertension (PVR ≤ 4 Wood Units) and severe pulmonary hypertension (PVR > 4 Wood Units). The utilization of a PVR cutoff value of 4.0 Wood Units provides enhanced prognostic capabilities for predicting mortality. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|